Status:
RECRUITING
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus）
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Type 2 Diabetes
Insulin Resistance
Eligibility:
All Genders
45-70 years
Brief Summary
This is a cross-sectional and longitudinal study to investigate the characteristic changes in Papez's circuit neural network activity and connectivity based on multimodal MRI, and through follow-up st...
Detailed Description
T2DM patients may have multidimensional cognitive impairment, which is related to the damage of key brain regions in Papez's circuit. The purpose of this study is to establish a prediction model for t...
Eligibility Criteria
Inclusion
- T2DM patients met the diagnostic criteria for diabetes (WHO, 1999) with a duration of 3-20 years; The control group met the criteria of fasting blood glucose \< 6.1mmol/l and glycosylated hemoglobin \< 5.7%;
- right-handed, aged 45-70 years, with ≥8 years of education;
- no contraindications to MRI scanning such as electronic and metal device implantation;
- The visual acuity or corrected visual acuity and binaural hearing can meet the needs of the evaluation, and can cooperate to complete the examination.
- without a history of substance abuse or dependence, evaluation is not used during the period of calm sleeping pills and antidepressants, not long-term use of drugs to improve cognitive.
Exclusion
- patients with acute metabolic complications or a history of severe hypoglycemia;
- severe heart, liver, lung, kidney and hematopoietic system diseases; Hyperthyroidism or hypothyroidism; Stroke, alzheimer's disease, epilepsy, Parkinson's disease and other neurological history; A history of mental illness such as depression, mania, or alcohol dependence; History of loss of consciousness due to neurological diseases or traumatic brain injury;
- one month before the laboratory examination, with a record and surgical trauma infection;
Key Trial Info
Start Date :
May 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06912321
Start Date
May 1 2024
End Date
December 31 2030
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China, 210000